Next-Generation Dual and Triple Receptor Agonists: Formulation of two dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) agonists such as tirzepatide and the upcoming triple GLP-1/GIP/glucagon agonists are a paradigm shift in the management of metabolic diseases
KEY FEATURES BPC-157 lyophilised research-grade peptide 5mg per vial Independent HPLC-MS verified to 99.67% purity (CoA on public Lab Results portal) Single-batch fill, single-batch chromatogram no blending across lots Synthesised in accredited contract laboratories with full QA paper trail Crimp-sealed, tamper-evident research vial in unbranded outer packaging Dispatched from Australia on Auspost Express with insulated cold-pack option SPECIFICATIONS Product Name BPC-157 Category Healing Research Peptides Grade Research grade laboratory use only Quantity 5mg per vial Form Lyophilised powder cake Purity 99.67% verified by HPLC-MS Appearance White to off-white lyophilised solid Storage 28 C lyophilised
Research suggests GLP-1RAs can increase angiogenesis (the growth of new blood vessels) and boost fibroblast activity (the cells responsible for producing collagen), potentially accelerating wound healing and promoting skin firmness
BPC-157 increases growth hormone receptors in fibroblasts, extending their lifespan and enhancing their ability to promote soft tissue regeneration [3]
Additionally, it has asked for expert testimonies to be excluded from future trials
Linear regression and Spearman correlation coefficients were calculated between treatment groups
.png)
